open access

Vol 7, No 3 (2003)
Prace oryginalne
Published online: 2003-07-21
Get Citation

Efficacy and Tolerance of Betaxolol in the Treatment of Patients with Hypertension and Coronary Heart Disease

Barbara Gryglewska, Tomasz Grodzicki
Nadciśnienie tętnicze 2003;7(3):157-162.

open access

Vol 7, No 3 (2003)
Prace oryginalne
Published online: 2003-07-21

Abstract

Background The objective of the study was to evaluate the efficacy and tolerance of betaxolol in the therapy of patients with hypertension (HT) and/or coronary heart disease (CHD) in primary care.
Material and methods Patients not receiving a beta blocker were enrolled in an open-label clinical trial. At entry, blood pressure (2 ×) and heart rate were measured and a questionnaire was fulfilled. Betaxolol at a dose of 10–20 mg/d was administered for 8 weeks and its efficacy and tolerance were assessed by the physician (using a 4-point scale) and the patient (3-point scale).
Results A total of 6881 patients (46% M) aged from 15 to 93 years (average 67 ± 11.4) were enrolled. CHD was diagnosed in 48% (46% CHD + HT), diabetes, in 15%. The drug was most often added to hypertension (ACEI - 53%, Ca-blockers - 19%, diuretics - 42%), lipid-lowering (37%), and anti-platelet (35%) treatment. The average administered dose was 16.6 mg. Treatment led to a significant drop in blood pressure from 165 ± 18.3/99 ± 10 mm Hg to 139.6 ± 13.6/84.2 ± 8.3 mm Hg, accompanied by reduction in heart rate from 84 ± 10.3 beats/min to 70.2 ± 8.3 beats/min, at good (55%) or very good (41%) tolerance and effectiveness (good - 53%, very good - 39%). Side effects occurred only in 6% of the patients. Treated patients did not report deterioration of sleep quality (no change + improvement, 98%), mood (no change + improvement, 98%), or sexual performance (91%).
Conclusions Betaxolol is a safe and effective medication in the treatment of patients with hypertension and coronary heart disease in primary care.

Abstract

Background The objective of the study was to evaluate the efficacy and tolerance of betaxolol in the therapy of patients with hypertension (HT) and/or coronary heart disease (CHD) in primary care.
Material and methods Patients not receiving a beta blocker were enrolled in an open-label clinical trial. At entry, blood pressure (2 ×) and heart rate were measured and a questionnaire was fulfilled. Betaxolol at a dose of 10–20 mg/d was administered for 8 weeks and its efficacy and tolerance were assessed by the physician (using a 4-point scale) and the patient (3-point scale).
Results A total of 6881 patients (46% M) aged from 15 to 93 years (average 67 ± 11.4) were enrolled. CHD was diagnosed in 48% (46% CHD + HT), diabetes, in 15%. The drug was most often added to hypertension (ACEI - 53%, Ca-blockers - 19%, diuretics - 42%), lipid-lowering (37%), and anti-platelet (35%) treatment. The average administered dose was 16.6 mg. Treatment led to a significant drop in blood pressure from 165 ± 18.3/99 ± 10 mm Hg to 139.6 ± 13.6/84.2 ± 8.3 mm Hg, accompanied by reduction in heart rate from 84 ± 10.3 beats/min to 70.2 ± 8.3 beats/min, at good (55%) or very good (41%) tolerance and effectiveness (good - 53%, very good - 39%). Side effects occurred only in 6% of the patients. Treated patients did not report deterioration of sleep quality (no change + improvement, 98%), mood (no change + improvement, 98%), or sexual performance (91%).
Conclusions Betaxolol is a safe and effective medication in the treatment of patients with hypertension and coronary heart disease in primary care.
Get Citation

Keywords

betaxolol; hypertension; coronary heart disease

About this article
Title

Efficacy and Tolerance of Betaxolol in the Treatment of Patients with Hypertension and Coronary Heart Disease

Journal

Arterial Hypertension

Issue

Vol 7, No 3 (2003)

Pages

157-162

Published online

2003-07-21

Bibliographic record

Nadciśnienie tętnicze 2003;7(3):157-162.

Keywords

betaxolol
hypertension
coronary heart disease

Authors

Barbara Gryglewska
Tomasz Grodzicki

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl